```html

Wet Macular Degeneration – Comprehensive Medical Guide

Overview

Wet macular degeneration (also called neovascular or exudative age‑related macular degeneration, AMD) is a progressive eye disease that affects the central portion of the retina known as the macula. Abnormal blood vessels grow underneath the macula, leak fluid or blood, and scar the delicate retinal tissue, leading to rapid loss of central vision.

The condition usually develops in one eye first, but up to 50 % of patients eventually have involvement of the second eye. It most commonly occurs in people over 60 years of age, but early‑onset cases have been reported in individuals in their 40s and 50s.

According to the Centers for Disease Control and Prevention (CDC), AMD is the leading cause of irreversible vision loss in adults over 65 in the United States, affecting roughly 11 million people. Of those, about 10‑15 % have the wet form, which accounts for ~90 % of severe vision loss associated with AMD.<sup>1</sup>

Symptoms

Symptoms often appear suddenly or progress quickly over weeks to months—much faster than the “dry” form of AMD. Common signs include:

• Distorted or wavy lines – Straight lines (e.g., letters on a page, telephone poles) appear bent or “wiggly.”
• Central visual loss – A dark or blurry spot develops in the middle of the visual field, making reading, facial recognition, and driving hazardous.
• Metamorphopsia – Objects may look smaller or larger than they are, especially straight edges.
• Colour perception changes – Colors may appear faded or washed out.
• Reduced ability to see fine details – Difficulty threading a needle, reading small print, or recognizing faces.
• Rapid onset of symptoms – Unlike dry AMD, which worsens gradually, wet AMD can deteriorate over days to weeks.
• Seeing “floaters” or dark spots – Blood or fluid leaking from abnormal vessels can create dark floaters.

If any of these symptoms appear, especially with sudden onset, prompt ophthalmic evaluation is essential.

Causes and Risk Factors

Underlying Pathophysiology

Wet AMD results from the growth of fragile, leaky blood vessels (choroidal neovascularization, CNV) beneath the retinal pigment epithelium (RPE). The process is driven by an imbalance between pro‑angiogenic factors—primarily vascular endothelial growth factor (VEGF)—and natural inhibitors.

Key Risk Factors

• Age – Risk rises sharply after age 60; prevalence doubles every decade thereafter.
• Genetics – Variants in the CFH (complement factor H) and ARMS2 genes increase susceptibility. A first‑degree relative with AMD raises risk 2‑3 times.<sup>2</sup>
• Smoking – Current smokers have a 2‑3‑fold higher risk; former smokers retain elevated risk for years.
• Race – Caucasians have the highest rates; African‑American and Asian populations have lower but still significant incidence.
• Cardiovascular disease – Hypertension, atherosclerosis, and elevated cholesterol are linked to increased VEGF activity.
• Obesity & diet – High body‑mass index and diets low in omega‑3 fatty acids and antioxidants (e.g., lutein, zeaxanthin) may contribute.
• UV light exposure – Chronic exposure to UV‑B radiation may accelerate retinal damage.
• History of dry AMD – Roughly 10‑15 % of patients with dry AMD progress to the wet form.
• Medications – Long‑term use of blood thinners (e.g., warfarin) or anabolic steroids can predispose to ocular bleeding.

Diagnosis

Early detection is critical because treatment is most effective within weeks of symptom onset.

Clinical Examination

• Visual acuity test – Determines the degree of central vision loss.
• Amsler grid – Patients look at a grid of straight lines; distortion indicates macular involvement.
• Fundoscopic examination – Direct visualization of the retina using an ophthalmoscope or slit‑lamp biomicroscopy with a special lens.

Imaging Studies

• Optical Coherence Tomography (OCT) – Provides cross‑sectional images of retinal layers, showing fluid accumulation, thickening, or scar tissue.
• Fluorescein Angiography (FA) – Intravenous dye highlights leaking vessels; classic “lacy‑wheel” pattern suggests CNV.
• Indocyanine Green Angiography (ICG) – Useful for deeper choroidal vessels and polypoidal lesions.

These tests are usually performed in a retinal specialty clinic. Blood tests are not required for diagnosis but may be ordered to assess systemic risk (e.g., lipid panel, HbA1c).

Treatment Options

While there is no cure, modern therapies can stabilize or even improve vision in many patients.

Anti‑VEGF Intravitreal Injections

The cornerstone of treatment. Medications block VEGF to prevent new vessel growth and reduce leakage.

• Aflibercept (Eylea) – Often given every 4–8 weeks after loading dose.
• Ranibizumab (Lucentis) – FDA‑approved for AMD; dosing similar to aflibercept.
• Bevacizumab (Avastin) – Off‑label but widely used due to lower cost; same schedule.
• Faricimab (Vabysmo) – Newer agent targeting both VEGF‑A and Ang‑2; dosing may be extended to 12‑16 weeks after initial loading.

Clinical trials (e.g., MARINA, ANCHOR) show average visual acuity gains of 5–10 letters after 2 years of regular injections.<sup>3</sup>

Photodynamic Therapy (PDT)

Used less frequently now but still an option for specific lesion types (e.g., polypoidal choroidal vasculopathy). A light‑activated drug (verteporfin) is infused and then activated by a laser, sealing abnormal vessels.

Laser Photocoagulation

Direct laser burns can destroy leaking vessels, but because the macula is highly specialized, this technique is reserved for extrafoveal lesions to avoid central scotoma.

Combination Therapy

Some physicians combine anti‑VEGF injections with PDT or steroids to reduce injection frequency.

Lifestyle & Adjunct Measures

• AREDS2 supplement regimen – High‑dose vitamins C, E, zinc, copper, lutein + zeaxanthin may slow progression of dry AMD and support overall retinal health.<sup>4</sup>
• Smoking cessation – Reduces oxidative stress and vascular inflammation.
• Blood pressure & cholesterol control – Statins and antihypertensives may lower VEGF stimulus.
• Dietary optimization – Emphasize leafy greens, fatty fish (omega‑3), nuts, and fruits.

Living with Wet Macular Degeneration

Day‑to‑Day Management

• Appointment adherence – Keep all injection appointments; missed doses can result in irreversible vision loss.
• Low‑vision aids – Magnifiers, high‑contrast reading glasses, screen‑reading software (e.g., ZoomText, VoiceOver).
• Environmental modifications – Use bright, well‑focused lighting, reduce glare with matte lenses, and organize living spaces to minimize obstacles.
• Driving considerations – Most states require a visual field test; discuss fitness to drive with an ophthalmologist.
• Emotional support – Vision loss can lead to depression or anxiety; counseling, support groups, or organizations such as the American Macular Degeneration Foundation can help.

Monitoring Progress

Patients should perform a daily self‑check with an Amsler grid and report any new distortion immediately. Keep a log of visual changes, injection dates, and side effects to share with your retina specialist.

Prevention

While genetics cannot be changed, many modifiable factors can lower the odds of developing wet AMD or slow progression from dry to wet forms.

• Quit smoking – Seek nicotine‑replacement therapy or prescription aids.
• Control systemic health – Maintain blood pressure < 130/80 mmHg, LDL < 100 mg/dL, and body‑mass index 18.5–24.9.
• Adopt a Mediterranean‑style diet – Rich in leafy greens, fish, olive oil, and nuts.
• Regular eye examinations – Yearly dilated exams after age 50; earlier if you have risk factors.
• Wear UV‑protective sunglasses – Block 99 % of UV‑A/B rays.
• Consider AREDS2 supplementation – Particularly for anyone with intermediate or advanced dry AMD.

Complications

If untreated, wet AMD can lead to:

• Permanent central scotoma – Irreversible blind spot in the center of vision.
• Fibrotic scarring – Scar tissue contracts the retina, further degrading visual acuity.
• Subretinal hemorrhage – Large bleeds can cause sudden, severe vision loss.
• Secondary glaucoma – Rarely, repeated injections increase intra‑ocular pressure.
• Psychological impact – Depression, social isolation, and reduced quality of life.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Age‑related macular degeneration. https://www.mayoclinic.org. Accessed May 2024.
2. National Eye Institute. Genetics of AMD. https://nei.nih.gov. 2023.
3. Rosenfeld PJ et al. Ranibizumab for neovascular AMD. NEJM. 2006;355:1419‑1431.
4. Age‑Related Eye Disease Study 2 Research Group. Lutein, zeaxanthin, and n‑3 fatty acids. JAMA. 2013;309(19):2005‑2015.

```